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Abstract
BACKGROUND: Cryptococcus species are the most prevalent opportunistic agents found in patients with HIV which 
may result in life-threatening cryptococcal meningitis (CM). A non-invasive way for diagnosis of CM is the detection of 
cryptococcal antigen (CrAg) in the blood to reduce either the mortality rate or the treatment complications associated 
with antiretroviral therapy. Not much information is available in CM among HIV patients in Iran. 
AIM: Thus, in the current study, we aimed to evaluate the prevalence of cryptococcal disease by antigen testing, possible 
associated factors, and outcomes in HIV-infected patients being managed in a referral HIV/TB hospital in Tehran-Iran. 
METHODS: In this cross-sectional study, blood samples were screened for CrAg using a rapid latex agglutination 
test between 2017 and 2018 at Masih Daneshvari Hospital (Tehran-Iran) as referral land center for HIV/TB patients. 
Based on CD4 counts, 106 HIV-positive infected patients including 101 (95.3%) males and 5 (4.7%) females with the 
mean ± standard deviation age of 42.40 ± 10.687 and 36.50 ± 6.403 years enrolled in the study. The patients were 
categorized into 4 groups, (a) <50, (b) 50–100, (c) 101–200, and (d)>200 CD4+ T cells/µL. Whole blood was obtained 
with EDTA (for flow cytometry of CD4 counts) or without for harvesting serum for determination of CrAg in serum.
RESULTS: The results showed only one positive case for CrAg, indicating that CrAg is rare in Iranian HIV patients 
(overall estimation is lower than 0.01%).
CONCLUSIONS: With the paucity of information about the prevalence of cryptococcosis in Iran, there is a need for 
better screening tests and strategies for detection of CrAg in addition to the prevention and treatment approaches of CM.
Edited by: Eli Djulejic
Citation: Kamali M, Tabarsi P, Badihi K, Mortaz E. The 
Prevalence of Cryptococcal Antigenemia in Serum of 
Human Immunodeficiency Viruses-infected Patients 
of Iran. Open Access Maced J Med Sci. 2020 Feb 05; 
8(A):6-9. https://doi.org/10.3889/oamjms.2020.2927
Keywords: Cryptococcal antigenemia; 
Cryptococcal antigen; CD4; HIV; Meningitis
*Correspondence: Esmaeil Mortaz, 
Clinical Tuberculosis and Epidemiology Research Center, 
National Research Institute for Tuberculosis and Lung 
Disease (NRITLD), Shahid Beheshti University of Medical 
Sciences, Tehran, Iran. 
E-mail: emortaz@gmail.com
Received: 18-Apr-2019
Revised: 06-Sep-2019
Accepted: 24-Dec-2019
Copyright: © 2020 Monireh Kamali, Payam Tabarsi, 
Khorshid Badihi, Esmaeil Mortaz
Funding: This research did not receive any financial 
support
Competing Interests: The authors have declared that no 
competing interests exist
Open Access: This is an open-access article distributed 
under the terms of the Creative Commons Attribution-
NonCommercial 4.0 International License (CC BY-NC 4.0)
Introduction
Cryptococcus species (mostly neoformans 
and gatti) are the most common opportunistic agents 
found in patients with HIV-infected patients leading to a 
fatal condition, referred to as cryptococcal meningitis 
(CM) [1,2]. It is associated with a high mortality rate 
among these patients with more than 600,000 deaths 
per year in 2009 and recent estimates from 2014 
indicate that over 160,000 (95% confidence interval 
113,600–193,900) cases of CM, including more than 
130,000 deaths occurred in sub-Saharan Africa [3,4]. CM 
remarkably occurs in sub-Saharan Africa and Southeast 
Asia, which are known as the major prevalent sites for 
HIV [5]. Data from epidemiological studies suggest that 
increasing cryptococcosis is associated with increasing 
HIV infections. On the other hand, the prevalence of 
cryptococcosis was decreased with the implication of 
antiretroviral therapy (ART) regimens, which may be 
indicated a tight association between cryptococcosis 
prevalence and the immune system function [6]. Early 
screening for detecting the presence of CM in HIV 
patients, especially those with CD4 counts <100/ml, is 
highly recommended by the World Health Organization 
(WHO). This early tests are cost-effective and on the other 
hand, able to increase the survival rate of patients with HIV 
with treatment [7]. In addition, one of the complications 
associated with starting ART in HIV patients with a latent 
cryptococcosis is immune reconstitution inflammatory 
syndrome (IRIS), which arises after considerable 
improvement in the immune system of the HIV patients 
and leads to the inflammation of meninges. In fact, it is 
a very life-threatening extremely decreases the survival 
rate of the infected individuals [8]. Thus, antifungal therapy 
before initiating ART is very important in HIV patients 
with concurrent cryptococcosis [9]. Early cryptococcosis 
infection is asymptomatic and treatable which is 
characterized by the presence of cryptococcus antigens 
in the blood [10]. In contrast, symptomatic cryptococcosis, 
leading to meningitis or pneumonia, is hardly treated with 
high coast drugs such as amphotericin B [11]. Thus, early 
diagnosis and preemptive treatment of cryptococcosis is 
considered as cost-effective approaches for the cure of 
patients with HIV. Early detection of CM is achievable 
through cryptococcal antigen (CrAg) lateral flow assay 
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(LFA) for cryptococcosis as a rapid and inexpensive 
assay. CrAg is rapid latex agglutination test with lower 
sensitivity and specificity compared with LFA. However, 
there are other tests such as direct microscopy through 
staining lumbar puncture specimens with India ink, PCR, 
and enzyme-linked immunosorbent assay [12]. To date, 
there is not much information that is available about CM 
among Iranian HIV patients. Therefore, we aimed to 
investigate the prevalence of cryptococcosis antigenemia 
among HIV-infected patients from July 2017 to July 2018 
in Masih Daneshvari hospital the referral center for HIV in 
land.
Materials and Methods
We conducted a cross-sectional study from 
July 2017 to July 2018. There were 106 HIV-positive 
subjects, including 101 male and 5 female, from Masih 
Daneshvari Hospital that is a national referral center for 
HIV Tehran-Iran.
The study was reviewed and approved by the 
University Ethics Committee. All procedures performed 
were in accordance with the ethical standards of the 
institutional and national research. After obtaining 
written consent to participate from the participants, 
demographic data were collected. Remel Cryptococcus 
Antigen Test Kit (Thermo Scientific™, USA), a rapid 
latex agglutination test was employed for qualitative or 
semi-quantitative detection of polysaccharide antigens 
associated with Cryptococcus neoformans infection in 
serum or CSF of patients. Frequency and percentage 
were reported for categorized variables. All data were 
analyzed with SPSS version 22 (SPSS Inc., Chicago, 
Illinois, USA). The normality of the data was evaluated 
by the Kolmogorov–Smirnov test. The Kruskal–Wallis H 
test was used to assess significant intergroup variations.
Results
In this study, 101 (95.3%) males and 5 (4.7%) 
females were screened for CrAg antigen. The mean age 
± standard deviation of them was 42.40 ± 10.687 and 
36.50 ± 6.403, respectively. About 50% of individuals were 
30–40 years old and other age groups have a relatively 
lower frequency. The demographic data were presented 
in Table 1. Based on the CD4 counts, the patients were 
categorized into the following groups: 33 (31.1%) of the 
subjects had CD4 counts of <50 cells/μL, 9 (8.5%) had 
CD4 counts of 50–100 cells/μL, 19 (17.9%) had CD4 
counts of 101–200 cells/μL and 42 (39.7%) with 
CD4 counts of >200 cells/μL, and 3 (2.8%) had missing 
CD4 cell counts. Pulmonary symptoms were negative for 
73 (70.9%) of the subjects and positive for 30 (29.1%) 
individuals. Furthermore, CNS symptoms were negative 
for 25 (24.3%) of the individuals and positive for 78 (75.7%) 
subjects. CrAg evaluation was positive in one patient 
41 years man with CD4 counts <50. He was from Bandar 
Abbas city, in the South of Iran with tropical climate while 
other subjects with negative CrAg results are not from 
cities with such climate. In fact, the prevalence of CrAg 
was <1% among whole patients with HIV (Table 2).
Table 2: Indicating for CD4+ T cell counts, clinical symptoms, 
and serum CrAg
Variable Group Frequency Percent
CD4 counts <50 cells/µL 33 31.1
50–100 cells/µL 9 8.5
101–200 cells/µL 19 17.9
>200 cells/µL 42 39.7
Missing CD4 cell count 3 2.8
Pulmonary symptoms Yes 32 30.2
No 74 69.8
CNS symptoms Yes 81 76.4
No 25 23.6
CrAg results Negative 105 99.1
Positive 1 0.9
CrAg: Cryptococcal antigen, CNS: Central nervous system.
The association of CNS symptoms and CrAg 
results is shown in Table 3. According to the results, 
91 (85.9%) subjects were presented negative CNS 
symptoms and CrAg, 1(0.9%) subjects were presented 
negative CNS symptom meanwhile positive CrAg 
results, and 14 (13.3%) subjects presented positive 
CNS symptoms meanwhile CrAg-negative results.
Table 3: Indicating for CNS symptoms in HIV patients with 
serum CrAg
CNS symptoms CrAg results Frequency Percent
Negative Negative 91 85.9
Positive 1 0.9
Positive Negative 14 13.2
Positive - -
CrAg: Cryptococcal antigen, CNS: Central nervous system.
Discussion
Cryptococcosis is an opportunistic infection 
which HIV patients due to the lower immune response 
have the highest prevalence with an average of 6%.
Cryptococci infection in HIV patients induces 
the life-threatening condition and usually leads to 
developing CM and considered approximately 15% of 
HIV-related deaths.
In addition, it is a contraindication of the 
early beginning of ART due to the IRIS phenomenon 
which arises after considerable improvement in the 
immune system of the HIV patients and leads to the 
Table 1: Demographic characteristics of HIV-infected patients
Variable Group Frequency Percent
Sex Male 101 95.3
Female 5 4.7
Age 0 (<20) 1 0.9
1 (20–29) 4 3.8
2 (30–39) 46 43.4
3 (40–49) 39 36.8
4 (50–59) 12 11.3
5 (≥60) 4 3.8
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inflammation of meninges [4,8]. Therefore, early 
detection and preemptive treatment of this infection is 
highly recommended due to the patient’s survival and 
treatment costs [10]. In this study, it was found that 
despite having neurologic and respiratory symptoms, 
the prevalence of cryptococcosis among the study 
of HIV patients was lower (1.0%). Among the 106 
participants of this study, only one person was positive 
for CrAg from a tropical climate area with poor hygiene 
and low resources setting which are favorable for the 
transmission of Cryptococcus species.
To make an appropriate decision for preparing 
national guidelines regarding the policies related to 
cryptococcus screening, it is highly recommended to 
assess the prevalence of cryptococcosis in different 
areas and different referral centers for HIV in the 
country for the prevalence. One of the best ways for 
estimating cryptococcosis prevalence is testing for 
the presence of CrAg using different screening tests. 
These screening tests not only provide a measure for 
assessing the outcome of successful strategies for the 
management of AID-associated complications but also 
could help the physicians to make the best decisions 
regarding the treatment options and also the timing of 
ART. Most of the screening studies have been done so 
far in sub-Saharan Africa and also in Southeast Asia. 
These two locations are known for having the most HIV 
prevalence and also their climate and poor settings 
support the survival and transmission of cryptococcosis.
Most of the retrospective and cross-sectional 
studies were done in these regions to support the 
WHO guidelines regarding the early screening tests 
for HIV patients with blood CD4 counts <100/µl and 
warrant for pre-emptive treatments which by oral 
fluconazole [13].
Thus, the WHO introduces CrAg antigenemia 
as an effective predictor of CM. In correspondence, 
Smith et al. estimated that the average prevalence of 
CrAg in Vietnam as a Southeast Asian countries around 
4% with a higher prevalence (6%) in South Vietnam 
compared to North (2%) Vietnam, which could indicate 
the necessity of investigating other parts of a country to 
determination and making a decision for the prevalence 
of cryptococcosis for employment of the right strategies 
for screening and treatment [14]. Moreover, a study 
done in Namibia for estimation of CrAg prevalence 
in immunocompromised adults reported an average 
prevalence of 3.3% among the study groups and 
suggested the implementation of screening tests 
for HIV patients with a CD4 count lower than 100/µl 
and employing preemptive treatment for the positive 
tested individuals [15]. Another study conducted in the 
Guinea-Bissau showed that 20% of ART-naive patients 
which were selected randomly, showed positive results 
for CrAg and thus emphasized on early screening 
and preemptive treatment for cryptococcosis [16]. In 
support of early screening and preemptive treatment for 
cryptococcosis, Longley et al. conducted a prospective 
study in South Africa and confirmed that preemptive 
treatment of cryptococcosis with fluconazole along with 
ART significantly reduced the risk of developing CM 
and CM associated death in HIV patients [17].
There is a paucity of data regarding the 
cryptococcosis prevalence in Iran and only one study has 
considered the concurrent infection of cryptococcosis with 
AIDS, which has found that among the 86 patients [18]. 
This patient had CD4 count <100/µl; no one was 
identified as a serum positive for CrAg through lateral 
flow immunochromatographic assay [18]. The lower ratio 
of prevalence in this study and the current one is not well 
understood and needs to be further explored.
In the current study, latex agglutination test was 
used which possesses lower sensitivity and specificity 
in comparison to LFA. However, there are some studies 
on the environmental distribution of Cryptococcus 
species in Iran; for example, Kamari et al. have shown 
that Cryptococcus species could be isolated from nearly 
18% of pigeon nests and around 12% of eucalyptus 
trees in Ilam, Iran [19]. Furthermore, Hedayati et al. in 
North of Iran found that 5.2% of collected samples 
from swallow (Hirundo rustica) excretions contained 
C. neoformans [20]. Soltani et al. showed that 2.5% of 
pigeon dropping samples from Isfahan, Iran, showed 
contamination with C. neoformans. Furthermore, a 
similar study by agha Kuchak Afshari et al. in North of 
Iran (Mazandaran) has revealed that 5% of the pigeon 
droppings showed contamination with C. neoformans [21]. 
These data collectively indicate the possibility that 
immunocompromised patients, especially those affected 
with HIV, could be infected with Cryptococcus species in 
different regions of Iran, and therefore it seems necessary 
to accurately estimate the prevalence of cryptococcal 
diseases in other parts of land, which requires integrated 
multicenter studies in land. In referral centers for HIV, 
which accept patients from different populations and 
areas, investigating the prevalence of opportunistic 
infections such as cryptococcosis could be very beneficial. 
Moreover, identification of the infected individuals can 
help decrease the chance of direct contact transmission 
by early treatment of the affected individuals in such 
centers containing immunodeficient patients.
Conclusions
We found a prevalence of CrAg of 
approximately 1% among HIV-infected patients 
with CD4 counts <50 cells/µL. With the paucity of 
information about the prevalence of cryptococcosis 
in Iran, there is a need for further investigation of the 
prevalence of this disease using rapid tests, such as 
latex agglutination test and LFA in different regions 
of Iran; so as to come to a national agreement about 
deciding whether to implement cryptococcus screening 
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tests and preemptive treatments in HIV care systems 
according to the WHO guidelines. Indeed, it requires 
the exact estimation of screening methods and cost 
burden of strategies compared with the cost burden of 
the treatment of cryptococcus-related meningitis and 
other complications.
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